Arbutus and Barinthus Bio Announce New Data From the IM-Prove II Trial Showing That the Addition of Nivolumab Increased Rates of Hbsag Loss in People With Chronic Hepatitis B
Arbutus和Barinthus Bio宣布了Im-Prove II试验的新数据,显示尼伏单抗的添加提高了慢性乙型肝炎患者Hbsag丢失的比率。
Arbutus and Barinthus Bio Announce New Data From the IM-Prove II Trial Showing That the Addition of Nivolumab Increased Rates of Hbsag Loss in People With Chronic Hepatitis B
Arbutus和Barinthus Bio宣布了Im-Prove II试验的新数据,显示尼伏单抗的添加提高了慢性乙型肝炎患者Hbsag丢失的比率。
使用浏览器的分享功能,分享给你的好友吧